Chembio Diagnostics, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • CEMI
  • 1d0.22%
  • 1w-1.52%
  • 1m3.41%
  • 1y-20.18%
ATH
  • ATH Price$306.00
  • ATH Date2001-01-17
  • % since ATH-99.85%
  • % to ATH67,152.75%
ATL
  • ATL Price$0.20
  • ATL Date2022-12-27
  • % from ATL127.50%
  • Last Low Price$0.2
  • Last Low Date2022-12-27
  • % From Last Low127.50%
IPO
  • IPO Price$1.25
  • % Current ROI USD-63.60%
  • ATH Price$306.00
  • % ROI ATH 15,300,000.00%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CEMI"]

Key Data [addtoany]

Current price $0.455
Sector Healthcare
Industry Diagnostics & Research
Today's High/Low $0/$0
Volume 0.00
Previous Close $0.454
52 Week High/Low $1.24/$0.19
Market Cap 16,710,285.00
P/E Ratio 0
Forward P/E 1 Yr. $6.72
Earnings Per Share(EPS) $0
Annualized Dividend $0
$0.455
[addtoany]

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases.
The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases.
The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally.
It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity